StockMacro
Menu

Alkermes

$44.94 +20% in 6 monthsMarket cap $7.6B

ALKS on XNAS, Health Care, Alkermes Inc. plc, job postings

Measures activity, not value. Not investment advice.

Quarterly revenue rose 22% to $480.1M, but the 12-month net loss was $351K.

  • BadShort interest is 12% of shares, 11.2 days to cover

Written by AI from the data on this page, 21 Nov 2026. Not investment advice.

Profile and fundamentals

From its SEC filings, 12 months to 30 Sep 2026

Alkermes PLC is a fully integrated biotechnology company that applies its proprietary technologies to research, develop, and commercialize pharmaceutical products designed for unmet medical needs in therapeutic areas. The company utilizes several to develop and commercialize products and, in so doing, access technological, financial, marketing, manufacturing, and other resources. Alkermes either purchases active drug products from third parties or receives them from its third-party licensees to formulate products using its technologies. It operates in U.S., which derives maximum revenue, Ireland and Rest of the world.

Industry
Pharmaceutical preparations (Health Care)
Employees
2,050
Website
alkermes.com
Listed
Nasdaq, US
Last results
3 Nov 2026
Next results
expected around 11 Jan 2027 (an estimate: a year ago it reported on 12 Jan 2026)
Revenue and net income per quarter. Quarter to 30 Sep 2026: revenue $480.1M, net income $16.3M.
Quarter to 31 Dec 2021: revenue $324.5M, net income $873KQuarter to 31 Dec 2021: revenue $324.5M, net income $873KQuarter to 31 Mar 2022: revenue $278.5M, net income -$35.9MQuarter to 31 Mar 2022: revenue $278.5M, net income -$35.9MQuarter to 30 Jun 2022: revenue $276.2M, net income -$30.1MQuarter to 30 Jun 2022: revenue $276.2M, net income -$30.1MQuarter to 30 Sep 2022: revenue $252.4M, net income -$64.0MQuarter to 30 Sep 2022: revenue $252.4M, net income -$64.0MQuarter to 31 Dec 2022: revenue $304.7M, net income -$28.3MQuarter to 31 Dec 2022: revenue $304.7M, net income -$28.3MQuarter to 31 Mar 2023: revenue $287.6M, net income -$41.8MQuarter to 31 Mar 2023: revenue $287.6M, net income -$41.8MQuarter to 30 Jun 2023: revenue $617.4M, net income $237.1MQuarter to 30 Jun 2023: revenue $617.4M, net income $237.1MQuarter to 30 Sep 2023: revenue $380.9M, net income $47.8MQuarter to 30 Sep 2023: revenue $380.9M, net income $47.8MQuarter to 31 Dec 2023: revenue $377.5M, net income $112.8MQuarter to 31 Dec 2023: revenue $377.5M, net income $112.8MQuarter to 31 Mar 2024: revenue $350.4M, net income $36.8MQuarter to 31 Mar 2024: revenue $350.4M, net income $36.8MQuarter to 30 Jun 2024: revenue $399.1M, net income $91.4MQuarter to 30 Jun 2024: revenue $399.1M, net income $91.4MQuarter to 30 Sep 2024: revenue $378.1M, net income $92.4MQuarter to 30 Sep 2024: revenue $378.1M, net income $92.4MQuarter to 31 Dec 2024: revenue $430.0M, net income $146.5MQuarter to 31 Dec 2024: revenue $430.0M, net income $146.5MQuarter to 31 Mar 2025: revenue $306.5M, net income $22.5MQuarter to 31 Mar 2025: revenue $306.5M, net income $22.5MQuarter to 30 Jun 2025: revenue $390.7M, net income $87.1MQuarter to 30 Jun 2025: revenue $390.7M, net income $87.1MQuarter to 30 Sep 2025: revenue $394.2M, net income $82.8MQuarter to 30 Sep 2025: revenue $394.2M, net income $82.8MQuarter to 31 Dec 2025: revenue $384.5M, net income $49.3MQuarter to 31 Dec 2025: revenue $384.5M, net income $49.3MQuarter to 31 Mar 2026: revenue $392.9M, net income -$66.5MQuarter to 31 Mar 2026: revenue $392.9M, net income -$66.5MQuarter to 30 Jun 2026: revenue $496.0M, net income $501KQuarter to 30 Jun 2026: revenue $496.0M, net income $501KQuarter to 30 Sep 2026: revenue $480.1M, net income $16.3MQuarter to 30 Sep 2026: revenue $480.1M, net income $16.3M
31 Dec 2021RevenueNet incomeNet losstallest bar $617.4M30 Sep 2026
See the numbers
Quarter toRevenueNet income
30 Sep 2026$480.1M$16.3M
30 Jun 2026$496.0M$501K
31 Mar 2026$392.9M-$66.5M
31 Dec 2025$384.5M$49.3M
30 Sep 2025$394.2M$82.8M
30 Jun 2025$390.7M$87.1M
31 Mar 2025$306.5M$22.5M
31 Dec 2024$430.0M$146.5M
30 Sep 2024$378.1M$92.4M
30 Jun 2024$399.1M$91.4M
31 Mar 2024$350.4M$36.8M
31 Dec 2023$377.5M$112.8M
30 Sep 2023$380.9M$47.8M
30 Jun 2023$617.4M$237.1M
31 Mar 2023$287.6M-$41.8M
31 Dec 2022$304.7M-$28.3M
30 Sep 2022$252.4M-$64.0M
30 Jun 2022$276.2M-$30.1M
31 Mar 2022$278.5M-$35.9M
31 Dec 2021$324.5M$873K
Fundamentals, 12 months to 30 Sep 2026
MeasureLatestYear beforePeer median
RevenueSales over the last 12 months reported. $1.8B $1.5B
Revenue growthRevenue of the last 12 months compared with the 12 months before. +15% +11%
Net incomeProfit after all costs and taxes over the last 12 months reported. Negative is a loss. -$351K $338.8M
EPS (diluted)Earnings per share: net income divided by the shares, counting options and convertibles. Left blank when the figures as filed do not fit today's share count (after a split). – –
Gross marginWhat is left of each dollar of sales after the direct cost of making the product or service. 82.9% 86.0% 73.2%
Operating marginOperating income as a share of sales: profit from the business before interest and taxes. 3.7% 23.6% -25.0%
Net marginNet income as a share of sales: what the owners keep of each dollar sold. -0.0% 22.3% -18.2%
Return on equityNet income of the last 12 months divided by shareholders' equity (the average of the latest balance sheet and the one a year earlier): the profit made on the owners' money. -0.0% -58.8%
Free cash flowCash from operations minus capital spending over the last 12 months: cash the business produced. $227.4M $490.9M
CashCash, cash equivalents and short-term investments on the latest balance sheet. $755.5M $1.1B
DebtShort- and long-term borrowings on the latest balance sheet. Operating leases are not counted. $1.5B –
Net debtDebt minus cash. Negative means the company holds more cash than it owes (net cash). $756.3M –
Debt to equityDebt divided by shareholders' equity on the latest balance sheet: how much is borrowed for each dollar the owners have in the company. Blank when equity is negative. 0.81 0.0
Book value per shareShareholders' equity (assets minus liabilities) on the latest balance sheet divided by the shares outstanding. $11.10
P/EPrice to earnings: market cap divided by net income of the last 12 months. What investors pay for one dollar of yearly profit. Blank when the company made a loss. loss 19.3
P/SPrice to sales: market cap divided by revenue of the last 12 months. 4.3 5.0
EV/SalesEnterprise value (market cap plus debt minus cash) divided by revenue of the last 12 months. 4.7 5.0
P/BPrice to book: market cap divided by shareholders' equity on the latest balance sheet. Blank when equity is negative. 4.0 2.0

Latest = 12 months to 30 Sep 2026; balance-sheet lines at its end. Peer median: companies in the same industry (SIC code), or the sector when the industry is small.

Peers nearest by market cap, its own industry first

CompanyMarket capP/EP/SRevenue growthNet margin
AlkermesALKS (this company) $7.6Bloss4.3+15%-0.0%
Kiniksa Pharmaceuticals InternationalKNSA $7.4B67.37.8+58%11.6%
Amneal PharmaceuticalsAMRX $7.4B55.22.3+8.9%4.2%
Rhythm PharmaceuticalsRYTM $7.8Bloss27.7+61%-69.0%
Protagonist TherapeuticsPTGX $7.9B23.214.4+164%62.0%
Summit TherapeuticsSMMT $8.0Bloss–––

Insider Buy/Sell Shares the company's insiders (directors, officers and owners of 10% or more) bought minus what they sold on the open market in the last 90 days, from their Form 4 filings.

-$698K

bought $0, sold $698K

Institutional holders The number of institutional investment managers (13F filers: funds, pensions, asset managers) reporting the stock, compared with the quarter before. 13F reports are public 45 days after quarter end and show long positions only.

-1.4%

410 13F filers vs 416

Institutional ownership Shares held by 13F filers at the latest quarter end, divided by the shares outstanding in the company's latest filing. Above 100% usually means a stale share count or double counting, and is marked.

over 100%

175.1M shares held by 13F filers (30 Sep 2026) of 168.0M outstanding (30 Oct 2026); above 100%: the share count is probably stale

Short interest Shares sold short and not yet bought back, divided by the shares outstanding in the company's latest filing. From FINRA's latest short interest report: FINRA reports twice a month and publishes 7 business days after the settlement date. Above 100% means a stale share count, and is marked.

12%

19.6M shares sold short (30 Oct 2026) of 168.0M outstanding (30 Oct 2026)

Days to cover Short interest divided by the stock's average daily trading volume, as FINRA publishes it: how many days of normal trading it would take short sellers to buy back every share. Latest report.

11.2

19.6M shares sold short (30 Oct 2026) divided by the stock's average daily volume, as FINRA publishes it

Short interest change How the number of shares sold short changed between FINRA's two latest reports, about two weeks apart.

+3.1%

19.0M shares sold short in the report before, 19.6M on 30 Oct 2026

Short sale volume Share of the stock's latest daily volume on FINRA-reported off-exchange venues that was sold short. Market makers sell short routinely, so 40% to 50% is normal; compare it with the company's own 1-year average in the cell's details. A daily flow, not short interest.

67%

67% of off-exchange volume on 20 Nov 2026 was short sales; 1-year average 55%

Open jobs Job postings open on the company's own careers site today, where we track it. Blank when we do not track this company's careers site yet.

–

We do not track this company's careers site yet.

Open jobs change How the number of open job postings changed over the last 30 days: total hiring demand, any job, any country. Shown only once we have tracked the company for 30 days.

–

We do not track this company's careers site yet.

Employees Total staff the company reported in its latest annual report (10-K), with the change from the year before when both years are reported.

–

No headcount in its annual reports in our data.

Visa hiring (foreign workers) Applications to hire foreign specialists on H-1B and E-3 visas certified by the Labor Department in the last 12 months, compared with the 12 months before. This is NOT total hiring: most hires need no visa. Open jobs shows total hiring where we track it.

+9.4%

35 vs 32 applications

Revenue growth Sales in the latest reported quarter compared with the same quarter a year earlier.

+22%

$480.1M vs $394.2M (quarter ended 30 Sep 2026)

Capital spending Money spent on buildings, machines and equipment in the latest quarter, compared with the same quarter a year earlier.

-80%

$3.4M vs $17.3M (quarter ended 30 Sep 2026)

Federal contracts Money the US government committed to the company in contracts and grants over the last 12 months.

–

No data for this company

Lobbying What the company reported spending on federal lobbying over the last four quarters.

$4.0M

4 quarters, $

Layoff notices Workers named in state WARN layoff notices over the last 12 months (employers must file them 60 days before a large layoff).

–

No data for this company

News (7d) Articles about the company published in the last 7 days, from our Google News collection (one search per company, every half hour). Blank when we do not collect news for this company.

8

8 articles in the last 7 days; its usual week has 3 (the median of the 26 weeks before).

News vs usual Articles in the last 7 days divided by the company's usual week: the median week of the 26 weeks before. Blank when the usual week has fewer than one article.

2.7×

8 articles in the last 7 days; its usual week has 3.

Unusual now sharp changes in the last 90 days, compared with its own past

  • New lobbying issue

Price $44.94 on 20 Nov 2026, +59% over 12 months (12-month range $27.20 to $55.22)

  • Sharp change
  • 8-K and other filings
  • Lobbying filing
Insider net buying (open market). Insiders sold a net $10.1M in the last 12 months (the 12 months before: -$18.9M).
H-1B/E-3 applications certified. H-1B/E-3 applications certified: 35 published in the last 12 months, +9.4% on the 12 months before.
Revenue per quarter. Revenue $480.1M in the latest quarter, +22% on a year earlier.
Capital spending per quarter. Capital spending $3.4M in the latest quarter, -80% on a year earlier.
Institutional holders (13F filers). 410 13F filers reported holding it in the latest 13F quarter, +22% on a year earlier.
Lobbying spend. Lobbying spend: $4.0M published in the last 12 months, +4.2% on the 12 months before.

Every point sits on the day the fact became public (filing acceptance or publication), not the day it happened; prices through 20 Nov 2026. Hover or tap a marker for the fact; click it for the evidence or the source. No data here for: federal obligations, workers in warn layoff notices.

See the numbers
Dated facts on the price chart (newest 100)
Became publicKindFact
22 Oct 2026Sharp changeLobbying on a new issue: lobbying on a new issue: TAR (2026-09-30)
20 Oct 2026Lobbying filingnew lobbying registration (HEALTH AND MEDICINE COUNSEL)
19 Oct 2026Lobbying filinglobbying engagement terminated (LMH STRATEGIC SOLUTIONS)
16 Sep 20268-K and other filingsDirector or officer change
16 Sep 2026Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
13 Aug 2026Lobbying filingnew lobbying registration (MONUMENT ADVOCACY)
8 Jul 20268-K and other filingsA major agreement ended
20 May 20268-K and other filingsDirector or officer change
19 May 2026Sharp changeMany funds opening a new position: many funds opening a new position, 59 vs usual 40.50 (2026-03-31); 1.1x the same period a year earlier
25 Feb 20268-K and other filingsDirector or officer change
25 Feb 2026Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
12 Feb 20268-K and other filingsA major agreement ended
12 Feb 20268-K and other filingsCompleted an acquisition or asset sale
13 Jan 2026Sharp changeShort interest spike: short interest spike, 21.8M vs usual 12.9M (2025-12-31); 2.0x the same period a year earlier
13 Jan 2026Lobbying filinglobbying engagement terminated (HOLLAND & KNIGHT LLP)
30 Dec 2025Sharp changeShort interest spike: short interest spike, 20.0M vs usual 12.7M (2025-12-15); 1.6x the same period a year earlier
12 Sep 20258-K and other filingsDirector or officer change
12 Sep 2025Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
21 May 20258-K and other filingsDirector or officer change
21 May 2025Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
18 Feb 2025Lobbying filingnew lobbying registration (BALLARD PARTNERS)
10 Jan 2025Lobbying filingnew lobbying registration (LMH STRATEGIC SOLUTIONS)
9 Jan 2025Lobbying filingnew lobbying registration (HOLLAND & KNIGHT LLP)
19 Dec 20248-K and other filingsA major agreement ended
31 May 20248-K and other filingsDirector or officer change
23 Apr 2024Sharp changeLobbying spend jump: lobbying spend jump, 1.0M vs usual 665K (2024-03-31); 0.5x the same period a year earlier
23 Apr 2024Lobbying filinglobbying engagement terminated (THE MCMANUS GROUP)
12 Apr 2024Lobbying filingnew lobbying registration (LMH STRATEGIC SOLUTIONS)
7 Mar 20248-K and other filingsDirector or officer change
27 Feb 2024Sharp changeQuarterly capital spending jump: quarterly capital spending jump, 17.0M vs usual 9.8M (2023-12-31); 1.7x the same period a year earlier
5 Feb 20248-K and other filingsDirector or officer change
19 Jan 2024Lobbying filinglobbying engagement terminated (TEAM HALLAHAN LLC)
16 Jan 2024Sharp changeShort interest spike: short interest spike, 14.0M vs usual 8.5M (2023-12-29); 1.5x the same period a year earlier
8 Dec 20238-K and other filingsDirector or officer change
8 Dec 2023Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
15 Nov 20238-K and other filingsCompleted an acquisition or asset sale
31 Oct 2023Sharp changeQuarterly revenue change: quarterly revenue change, 380.9M vs usual 290.9M (2023-09-30); 1.5x the same period a year earlier
21 Oct 2023Lobbying filinglobbying engagement terminated (FEDERAL STREET STRATEGIES, LLC)
20 Oct 2023Lobbying filinglobbying engagement terminated (THE MCMANUS GROUP)
1 Aug 2023Sharp changeQuarterly revenue change: quarterly revenue change, 617.4M vs usual 290.9M (2023-06-30); 2.2x the same period a year earlier
6 Jul 20238-K and other filingsDirector or officer change
6 Jul 2023Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
7 Jul 20228-K and other filingsDirector or officer change
26 May 20228-K and other filingsDirector or officer change
26 May 2022Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
23 Mar 2022Lobbying filinglobbying engagement terminated (TREMONT STRATEGIES GROUP LLC)
22 Mar 2022Lobbying filingnew lobbying registration (THE MCMANUS GROUP)
7 Feb 2022Lobbying filingnew lobbying registration (TREMONT STRATEGIES GROUP LLC)
13 Jan 2022Lobbying filinglobbying engagement terminated (CROSSROADS STRATEGIES, LLC)
Insider net buying (open market)
Month from 1 Feb 2022: -$355K published
Month from 1 Mar 2022: $10K published
Month from 1 Apr 2022: -$2.6M published
Month from 1 May 2022: -$12.9M published
Month from 1 Jun 2022: -$211K published
Month from 1 Nov 2022: $816K published
Month from 1 May 2023: -$2.1M published
Month from 1 Jun 2023: -$172K published
Month from 1 Feb 2024: -$162K published
Month from 1 Mar 2024: -$293K published
Month from 1 Nov 2024: -$2.2M published
Month from 1 Dec 2024: -$2.8M published
Month from 1 Feb 2025: -$15.3M published
Month from 1 Mar 2025: -$66K published
Month from 1 Jun 2025: -$210K published
Month from 1 Oct 2025: -$284K published
Month from 1 Nov 2025: -$273K published
Month from 1 Dec 2025: -$230K published
Month from 1 Jan 2026: -$262K published
Month from 1 Feb 2026: -$2.4M published
Month from 1 Mar 2026: -$769K published
Month from 1 Apr 2026: -$390K published
Month from 1 May 2026: -$1.1M published
Month from 1 Jun 2026: -$553K published
Month from 1 Jul 2026: -$574K published
Month from 1 Aug 2026: -$3.1M published
Month from 1 Sep 2026: -$521K published
Month from 1 Oct 2026: -$83K published
Month from 1 Nov 2026: -$94K published
H-1B/E-3 applications certified
Quarter from 1 Jan 2022: 2 published
Quarter from 1 Apr 2022: 6 published
Quarter from 1 Jul 2022: 2 published
Quarter from 1 Oct 2022: 4 published
Quarter from 1 Jan 2023: 2 published
Quarter from 1 Apr 2023: 3 published
Quarter from 1 Jul 2023: 7 published
Quarter from 1 Oct 2023: 5 published
Quarter from 1 Jan 2024: 7 published
Quarter from 1 Apr 2024: 2 published
Quarter from 1 Jul 2024: 7 published
Quarter from 1 Oct 2024: 4 published
Quarter from 1 Jan 2025: 6 published
Quarter from 1 Apr 2025: 4 published
Quarter from 1 Jul 2025: 13 published
Quarter from 1 Oct 2025: 9 published
Quarter from 1 Jan 2026: 2 published
Quarter from 1 Apr 2026: 7 published
Quarter from 1 Jul 2026: 13 published
Quarter from 1 Oct 2026: 13 published
Revenue per quarter
Quarter ended 31 Dec 2021: $324.5M, +16% on a year earlier; public on 17 Feb 2022
Quarter ended 31 Mar 2022: $278.5M, +11% on a year earlier; public on 28 Apr 2022
Quarter ended 30 Jun 2022: $276.2M, -9.1% on a year earlier; public on 28 Jul 2022
Quarter ended 30 Sep 2022: $252.4M, -14% on a year earlier; public on 3 Nov 2022
Quarter ended 31 Dec 2022: $304.7M, -6.1% on a year earlier; public on 17 Feb 2023
Quarter ended 31 Mar 2023: $287.6M, +3.2% on a year earlier; public on 27 Apr 2023
Quarter ended 30 Jun 2023: $617.4M, +124% on a year earlier; public on 27 Jul 2023
Quarter ended 30 Sep 2023: $380.9M, +51% on a year earlier; public on 26 Oct 2023
Quarter ended 31 Dec 2023: $377.5M, +24% on a year earlier; public on 22 Feb 2024
Quarter ended 31 Mar 2024: $350.4M, +22% on a year earlier; public on 2 May 2024
Quarter ended 30 Jun 2024: $399.1M, -35% on a year earlier; public on 25 Jul 2024
Quarter ended 30 Sep 2024: $378.1M, -0.7% on a year earlier; public on 25 Oct 2024
Quarter ended 31 Dec 2024: $430.0M, +14% on a year earlier; public on 13 Feb 2025
Quarter ended 31 Mar 2025: $306.5M, -13% on a year earlier; public on 2 May 2025
Quarter ended 30 Jun 2025: $390.7M, -2.1% on a year earlier; public on 30 Jul 2025
Quarter ended 30 Sep 2025: $394.2M, +4.2% on a year earlier; public on 29 Oct 2025
Quarter ended 31 Dec 2025: $384.5M, -11% on a year earlier; public on 26 Feb 2026
Quarter ended 31 Mar 2026: $392.9M, +28% on a year earlier; public on 6 May 2026
Quarter ended 30 Jun 2026: $496.0M, +27% on a year earlier; public on 29 Jul 2026
Quarter ended 30 Sep 2026: $480.1M, +22% on a year earlier; public on 4 Nov 2026
Capital spending per quarter
Quarter ended 31 Dec 2021: $8.7M, +59% on a year earlier; public on 17 Feb 2022
Quarter ended 31 Mar 2022: $7.8M, -2.4% on a year earlier; public on 28 Apr 2022
Quarter ended 30 Jun 2022: $10.0M, +52% on a year earlier; public on 28 Jul 2022
Quarter ended 30 Sep 2022: $10.5M, +118% on a year earlier; public on 3 Nov 2022
Quarter ended 31 Dec 2022: $10.0M, +16% on a year earlier; public on 17 Feb 2023
Quarter ended 31 Mar 2023: $6.9M, -12% on a year earlier; public on 27 Apr 2023
Quarter ended 30 Jun 2023: $9.7M, -2.6% on a year earlier; public on 27 Jul 2023
Quarter ended 30 Sep 2023: $14.5M, +38% on a year earlier; public on 26 Oct 2023
Quarter ended 31 Dec 2023: $17.0M, +70% on a year earlier; public on 22 Feb 2024
Quarter ended 31 Mar 2024: $8.3M, +22% on a year earlier; public on 2 May 2024
Quarter ended 30 Jun 2024: $7.1M, -27% on a year earlier; public on 25 Jul 2024
Quarter ended 30 Sep 2024: $8.3M, -43% on a year earlier; public on 25 Oct 2024
Quarter ended 31 Dec 2024: $9.8M, -43% on a year earlier; public on 13 Feb 2025
Quarter ended 31 Mar 2025: $10.1M, +21% on a year earlier; public on 2 May 2025
Quarter ended 30 Jun 2025: $13.0M, +83% on a year earlier; public on 30 Jul 2025
Quarter ended 30 Sep 2025: $17.3M, +110% on a year earlier; public on 29 Oct 2025
Quarter ended 31 Mar 2026: $4.1M, -60% on a year earlier; public on 6 May 2026
Quarter ended 30 Jun 2026: $8.1M, -37% on a year earlier; public on 29 Jul 2026
Quarter ended 30 Sep 2026: $3.4M, -80% on a year earlier; public on 4 Nov 2026
Institutional holders (13F filers)
31 Dec 2021 report: 197; public on 14 Feb 2022
31 Mar 2022 report: 232; public on 16 May 2022
30 Jun 2022 report: 255; public on 15 Aug 2022
30 Sep 2022 report: 250; public on 14 Nov 2022
31 Dec 2022 report: 255; public on 14 Feb 2023
31 Mar 2023 report: 247; public on 15 May 2023
30 Jun 2023 report: 268; public on 14 Aug 2023
30 Sep 2023 report: 282; public on 14 Nov 2023
31 Dec 2023 report: 289; public on 14 Feb 2024
31 Mar 2024 report: 321; public on 15 May 2024
30 Jun 2024 report: 304; public on 14 Aug 2024
30 Sep 2024 report: 321; public on 14 Nov 2024
31 Dec 2024 report: 329; public on 14 Feb 2025
31 Mar 2025 report: 355; public on 15 May 2025
30 Jun 2025 report: 335; public on 14 Aug 2025
30 Sep 2025 report: 335; public on 14 Nov 2025
31 Dec 2025 report: 350; public on 17 Feb 2026
31 Mar 2026 report: 377; public on 15 May 2026
30 Jun 2026 report: 416; public on 14 Aug 2026
30 Sep 2026 report: 410; public on 16 Nov 2026
Lobbying spend
Quarter from 1 Jan 2022: $590K published
Quarter from 1 Apr 2022: $1.1M published
Quarter from 1 Jul 2022: $580K published
Quarter from 1 Oct 2022: $630K published
Quarter from 1 Jan 2023: $550K published
Quarter from 1 Apr 2023: $1.9M published
Quarter from 1 Jul 2023: $690K published
Quarter from 1 Oct 2023: $640K published
Quarter from 1 Jan 2024: $700K published
Quarter from 1 Apr 2024: $1.0M published
Quarter from 1 Jul 2024: $470K published
Quarter from 1 Oct 2024: $550K published
Quarter from 1 Jan 2025: $550K published
Quarter from 1 Apr 2025: $1.5M published
Quarter from 1 Jul 2025: $890K published
Quarter from 1 Oct 2025: $900K published
Quarter from 1 Jan 2026: $930K published
Quarter from 1 Apr 2026: $1.1M published
Quarter from 1 Jul 2026: $990K published
Quarter from 1 Oct 2026: $970K published

What is unusual now

Latest records

The names and amounts behind the totals, newest first

Last 90 days: 4 sales, $698K; no purchases. Open-market trades by officers, directors and 10% owners.

FiledInsiderTradeSharesPriceValueSource
3 Nov 2026David Joseph GaffinEVP, CLO, Alkermes, Inc.Sellplanned in advance (10b5-1)2,035$46.17$94KForm 4
2 Oct 2026David Joseph GaffinEVP, CLO, Alkermes, Inc.Sellplanned in advance (10b5-1)2,034$41.03$83KForm 4
3 Sep 2026David Joseph GaffinEVP, CLO, Alkermes, Inc.Sellplanned in advance (10b5-1)2,034$48.01$98KForm 4
1 Sep 2026Craig C. HopkinsonEVP R&D, Chief Medical OfficerSellplanned in advance (10b5-1); after exercising options9,000$46.99$423KForm 4
17 Aug 2026Christian Todd NicholsSVP, Chief Commercial OfficerSellplanned in advance (10b5-1)7,576$49.23$373KForm 4
3 Aug 2026Craig C. HopkinsonEVP R&D, Chief Medical OfficerSellplanned in advance (10b5-1); after exercising options9,000$48.58$437KForm 4
3 Aug 2026David Joseph GaffinEVP, CLO, Alkermes, Inc.Sellplanned in advance (10b5-1)2,034$48.58$99KForm 4
3 Aug 2026nancy lynn snyderman MdDirectorSellafter exercising options44,472$50.35$2.2MForm 4

410 institutions reported shares at the end of Q3 2026, 100% of the shares outstanding; 46 opened a position, 52 sold out. From 13F reports.

InstitutionShares% of companyValueChange vs Q2 2026
BlackRock, Inc.28.7M17.1%$1.2B-532K-1.8%
State Street Corp10.1M6.03%$410.5M+971K+11%
Baker Bros. Advisors LP10.0M5.96%$405.7MNo change
Vanguard Portfolio Management LLC9.5M5.63%$383.3M-32K-0.3%
Vanguard Capital Management LLC7.5M4.47%$304.0M-12K-0.2%
Renaissance Technologies LLC6.5M3.86%$263.1M+33K+0.5%
Deep Track Capital, LP4.5M2.68%$182.3M+500K+12%
Geode Capital Management, LLC4.4M2.64%$179.8M-41K-0.9%
T. Rowe Price Associates Inc4.0M2.41%-2.7M-40%
Holocene Advisors, LP3.5M2.06%$140.1M-144K-4.0%

Federal contracts

All 1 federal contracts

No new award in 12 months; the latest was signed 30 Sep 2010. New awards only; later changes to an award are not listed.

SignedAgencyAmountWhat forSource
30 Sep 2010Department of Health and Human ServicesNational Institutes of Health$2.3MCLINICAL ADVANCEMENT OF RDC-0313-BUPRENORPHINE: A NOVEL APPROACH TO OPIOID RECEPGrantUSAspending

Company events

All 54 company events

In 12 months: 3 major agreements, 3 director or officer changes, 2 agreements ended, 1 completed deal. Results releases and routine reports are left out.

FiledWhat happenedSource
12 Nov 2026Entered settlement and license agreement with Teva Pharmaceuticals resolving LYBALVI patent suit; Teva license starts Nov 12, 20398-K
16 Sep 2026Director or officer change8-K
12 Aug 2026Signed a major agreement8-K
8 Jul 2026A major agreement ended8-K
20 May 2026Director or officer changeSame filing: shareholder vote results8-K
25 Feb 2026Director or officer change8-K
12 Feb 2026Signed a major agreement; A major agreement ended; Completed an acquisition or asset saleSame filing: took on new debt8-K
19 Nov 2025Signed a major agreementSame filing: took on new debt8-K

Reported lobbying spend: $970K in Q3 2026, $990K in Q2 2026. Rows are lobbying firms hired or let go; amounts are reported per quarter, not per firm here.

DateChangeLobbying firmIssueSource
30 Jun 2026EndedLMH Strategic Solutionsfor Avadel Pharmaceuticals, PLCPrescription Drug Competition Issues. H.R.4692/S.574 - Increasing Prescription Drug Competition Act. VA Appropriations Request.PharmacyFiling
29 Jun 2026NewMonument Advocacyfor Alkermes Inc.Issues related to Medicare.Medicare/MedicaidFiling
1 Jun 2026NewHealth And Medicine Counselfor Alkermes, IncFY28 Appropriations, Sleep Awareness and Education ActivitiesBudget, Health issuesFiling
31 Dec 2025EndedHolland & Knight LLPfor Alkermes, Inc.Tax Reform - Restoring the Orphan Drug Tax Credit.TaxationFiling
15 Jan 2025NewBallard Partnersfor Alkermes, Inc.Provide guidance and advice regarding mental health, public health and regulatory reform.Health issuesFiling
1 Jan 2025NewLMH Strategic Solutionsfor Alkermes, Inc.Medicare/Medicaid issues. ORPHAN Cures Act.Medicare/MedicaidFiling
12 Nov 2024NewHolland & Knight LLPfor Alkermes, Inc.Tax Reform - Restoring the Orphan Drug Tax CreditTaxationFiling
1 Mar 2024NewLMH Strategic Solutionsfor Avadel Pharmaceuticals, PLCPrescription drug competition issues.PharmacyFiling

The 5 newest of 158 articles that name the company.

Timeline

Timeline

Changes and notable records, by the date each became public

  1. 22 Oct 2026Lobbying change

    lobbying on a new issue.

    See the evidence
    New
    ['TAR']
    Rule
    only points whose every posting (and value revision) is at or before as_of
    Field
    issue_codes
    Metric
    lobbying.filings_count
    Point id
    4288424
  2. 20 Oct 2026Lobbying record

    ALKERMES, INC: new lobbying registration (HEALTH AND MEDICINE COUNSEL) (dated 1 Jun 2026)

  3. 19 Oct 2026Lobbying record

    AVADEL PHARMACEUTICALS, PLC: lobbying engagement terminated (LMH STRATEGIC SOLUTIONS) (dated 30 Jun 2026)

  4. 16 Sep 2026Filings change

    filed a director or officer change (8-K item 5.02), its first in 90 days.

    Item 5.02 covers departures and appointments alike, so this never counts toward a “several things at once”.

    See the evidence (1 source record)
    Filings in the window
    1

    Fires on an 8-K with item 5.02 after 90 days without one.

  5. 16 Sep 2026Filings record

    Director or officer change

  6. 13 Aug 2026Lobbying record

    ALKERMES INC.: new lobbying registration (MONUMENT ADVOCACY) (dated 29 Jun 2026)

  7. 8 Jul 2026Filings record

    A major agreement ended

  8. 20 May 2026Filings record

    Director or officer change

  9. 15 May 2026Institutional holdings change

    saw 59 13F filers open a new position in the quarter ended 31 Mar 2026, 1.1× the same quarter last year.

    Same quarter last year: 55; its normal quarter is 40.5.

    See the evidence
    This period
    59 (the quarter ended 31 Mar 2026)
    Normal quarter (median of 8 earlier)
    40.5
    Typical spread (median absolute deviation)
    3.5
    How far from its usual level
    +3.6
    Same quarter last year
    55
    History used
    4,565 days
    2024-03-31: 482024-06-30: 382024-09-30: 452024-12-31: 362025-03-31: 552025-06-30: 392025-09-30: 382025-12-31: 422026-03-31: 59
    the quarter ended 31 Mar 20268 earlier quartersnormal: 40.5

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 6+ earlier periods, 730+ days of history and a value of at least 20.

    Check it at the source: SEC Form 13F data sets.

  10. 25 Feb 2026Filings change

    filed a director or officer change (8-K item 5.02), its first in 90 days.

    Item 5.02 covers departures and appointments alike, so this never counts toward a “several things at once”.

    See the evidence (1 source record)
    Filings in the window
    1

    Fires on an 8-K with item 5.02 after 90 days without one.

  11. 25 Feb 2026Filings record

    Director or officer change

  12. 12 Feb 2026Filings record

    Completed an acquisition or asset sale

  13. 12 Feb 2026Filings record

    A major agreement ended

  14. 13 Jan 2026Short interest and volume change

    had 21.8M shares sold short in the 31 Dec 2025 report, 2.0× the same report last year.

    Same report last year: 10.7M; its normal report is 12.9M.

    See the evidence
    This period
    21.8M (the 31 Dec 2025 report)
    Normal report (median of 24 earlier)
    12.9M
    Typical spread (median absolute deviation)
    1.5M
    How far from its usual level
    +4.0
    Same report last year
    10.7M
    History used
    2,924 days
    2024-12-31: 10.7M2025-01-15: 11.4M2025-01-31: 10.8M2025-02-14: 11.6M2025-02-28: 14.0M2025-03-14: 13.0M2025-03-31: 11.0M2025-04-15: 12.4M2025-04-30: 12.8M2025-05-15: 11.3M2025-05-30: 11.6M2025-06-13: 10.6M2025-06-30: 11.9M2025-07-15: 12.6M2025-07-31: 13.8M2025-08-15: 13.8M2025-08-29: 13.3M2025-09-15: 15.1M2025-09-30: 15.2M2025-10-15: 14.4M2025-10-31: 15.9M2025-11-14: 17.3M2025-11-28: 18.8M2025-12-15: 20.0M2025-12-31: 21.8M
    the 31 Dec 2025 report24 earlier reportsnormal: 12.9M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  15. 13 Jan 2026Lobbying record

    ALKERMES, INC.: lobbying engagement terminated (HOLLAND & KNIGHT LLP) (dated 31 Dec 2025)

  16. 25 Dec 2025Short interest and volume change

    had 20.0M shares sold short in the 15 Dec 2025 report, 1.6× the same report last year.

    Same report last year: 12.5M; its normal report is 12.7M.

    See the evidence
    This period
    20.0M (the 15 Dec 2025 report)
    Normal report (median of 24 earlier)
    12.7M
    Typical spread (median absolute deviation)
    1.3M
    How far from its usual level
    +3.8
    Same report last year
    12.5M
    History used
    2,908 days
    2024-12-13: 12.5M2024-12-31: 10.7M2025-01-15: 11.4M2025-01-31: 10.8M2025-02-14: 11.6M2025-02-28: 14.0M2025-03-14: 13.0M2025-03-31: 11.0M2025-04-15: 12.4M2025-04-30: 12.8M2025-05-15: 11.3M2025-05-30: 11.6M2025-06-13: 10.6M2025-06-30: 11.9M2025-07-15: 12.6M2025-07-31: 13.8M2025-08-15: 13.8M2025-08-29: 13.3M2025-09-15: 15.1M2025-09-30: 15.2M2025-10-15: 14.4M2025-10-31: 15.9M2025-11-14: 17.3M2025-11-28: 18.8M2025-12-15: 20.0M
    the 15 Dec 2025 report24 earlier reportsnormal: 12.7M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  17. 12 Sep 2025Filings change

    filed a director or officer change (8-K item 5.02), its first in 90 days.

    Item 5.02 covers departures and appointments alike, so this never counts toward a “several things at once”.

    See the evidence (1 source record)
    Filings in the window
    1

    Fires on an 8-K with item 5.02 after 90 days without one.

  18. 12 Sep 2025Filings record

    Director or officer change

  19. 21 May 2025Filings change

    filed a director or officer change (8-K item 5.02), its first in 90 days.

    Item 5.02 covers departures and appointments alike, so this never counts toward a “several things at once”.

    See the evidence (1 source record)
    Filings in the window
    1

    Fires on an 8-K with item 5.02 after 90 days without one.

  20. 21 May 2025Filings record

    Director or officer change

  21. 18 Feb 2025Lobbying record

    ALKERMES, INC.: new lobbying registration (BALLARD PARTNERS) (dated 15 Jan 2025)

  22. 10 Jan 2025Lobbying record

    ALKERMES, INC.: new lobbying registration (LMH STRATEGIC SOLUTIONS) (dated 1 Jan 2025)

  23. 9 Jan 2025Lobbying record

    ALKERMES, INC.: new lobbying registration (HOLLAND & KNIGHT LLP) (dated 12 Nov 2024)

  24. 19 Dec 2024Filings record

    A major agreement ended

  25. 31 May 2024Filings record

    Director or officer change

  26. 23 Apr 2024Lobbying change

    reported $1.0M of lobbying spend for the quarter ended 31 Mar 2024, 45% below the same quarter last year.

    Same quarter last year: $1.9M; its normal quarter is $665K.

    See the evidence
    This period
    $1.0M (the quarter ended 31 Mar 2024)
    Normal quarter (median of 8 earlier)
    $665K
    Typical spread (median absolute deviation)
    $60K
    How far from its usual level
    +3.9
    Same quarter last year
    $1.9M
    History used
    5,388 days
    2022-03-31: $1.1M2022-06-30: $580K2022-09-30: $630K2022-12-31: $550K2023-03-31: $1.9M2023-06-30: $690K2023-09-30: $640K2023-12-31: $700K2024-03-31: $1.0M
    the quarter ended 31 Mar 20248 earlier quartersnormal: $665K

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 6+ earlier periods, 730+ days of history and a value of at least $100K.

    Check it at the source: Senate/House lobbying disclosures (LDA).

  27. 23 Apr 2024Lobbying record

    AVADEL PHARMACEUTICALS: lobbying engagement terminated (THE MCMANUS GROUP) (dated 29 Feb 2024)

  28. 12 Apr 2024Lobbying record

    AVADEL PHARMACEUTICALS, PLC: new lobbying registration (LMH STRATEGIC SOLUTIONS) (dated 1 Mar 2024)

  29. 7 Mar 2024Filings record

    Director or officer change

  30. 27 Feb 2024Financials change

    spent $17.0M on capital projects in the quarter ended 31 Dec 2023, 1.7× the same quarter last year.

    Same quarter last year: $10.0M; its normal quarter is $9.8M.

    See the evidence
    This period
    $17.0M (the quarter ended 31 Dec 2023)
    Normal quarter (median of 8 earlier)
    $9.8M
    Typical spread (median absolute deviation)
    $906K
    How far from its usual level
    +5.4
    Same quarter last year
    $10.0M
    History used
    4,748 days
    2021-12-31: $8.7M2022-03-31: $7.8M2022-06-30: $10.0M2022-09-30: $10.5M2022-12-31: $10.0M2023-03-31: $6.9M2023-06-30: $9.7M2023-09-30: $14.5M2023-12-31: $17.0M
    the quarter ended 31 Dec 20238 earlier quartersnormal: $9.8M

    Fires when the period is at least 3.0 robust standard deviations above the company's own median, with 6+ earlier periods, 540+ days of history and a value of at least $5.0M.

    Check it at the source: SEC EDGAR quarterly reports.

  31. 5 Feb 2024Filings record

    Director or officer change

  32. 19 Jan 2024Lobbying record

    ALKERMES, INC.: lobbying engagement terminated (TEAM HALLAHAN LLC) (dated 31 Dec 2023)

  33. 11 Jan 2024Short interest and volume change

    had 14.0M shares sold short in the 29 Dec 2023 report, 1.5× the same report last year.

    Same report last year: 9.2M; its normal report is 8.5M.

    See the evidence
    This period
    14.0M (the 29 Dec 2023 report)
    Normal report (median of 24 earlier)
    8.5M
    Typical spread (median absolute deviation)
    887K
    How far from its usual level
    +4.2
    Same report last year
    9.2M
    History used
    2,191 days
    2022-12-30: 9.2M2023-01-13: 9.4M2023-01-31: 9.1M2023-02-15: 9.0M2023-02-28: 9.0M2023-03-15: 9.5M2023-03-31: 9.3M2023-04-14: 8.8M2023-04-28: 7.6M2023-05-15: 7.5M2023-05-31: 7.1M2023-06-15: 6.4M2023-06-30: 5.8M2023-07-14: 6.1M2023-07-31: 6.1M2023-08-15: 8.2M2023-08-31: 9.5M2023-09-15: 9.7M2023-09-29: 8.7M2023-10-13: 7.3M2023-10-31: 8.0M2023-11-15: 8.0M2023-11-30: 7.8M2023-12-15: 9.7M2023-12-29: 14.0M
    the 29 Dec 2023 report24 earlier reportsnormal: 8.5M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  34. 8 Dec 2023Filings change

    filed a director or officer change (8-K item 5.02), its first in 90 days.

    Item 5.02 covers departures and appointments alike, so this never counts toward a “several things at once”.

    See the evidence (1 source record)
    Filings in the window
    1

    Fires on an 8-K with item 5.02 after 90 days without one.

  35. 8 Dec 2023Filings record

    Director or officer change

  36. 15 Nov 2023Filings record

    Completed an acquisition or asset sale

  37. 31 Oct 2023Financials change

    reported revenue of $380.9M for the quarter ended 30 Sep 2023, 1.5× the same quarter last year.

    Same quarter last year: $252.4M; its normal quarter is $290.9M.

    See the evidence
    This period
    $380.9M (the quarter ended 30 Sep 2023)
    Normal quarter (median of 8 earlier)
    $290.9M
    Typical spread (median absolute deviation)
    $14.2M
    How far from its usual level
    +3.1
    Same quarter last year
    $252.4M
    History used
    4,748 days
    2021-09-30: $294.1M2021-12-31: $324.5M2022-03-31: $278.5M2022-06-30: $276.2M2022-09-30: $252.4M2022-12-31: $304.7M2023-03-31: $287.6M2023-06-30: $617.4M2023-09-30: $380.9M
    the quarter ended 30 Sep 20238 earlier quartersnormal: $290.9M

    Fires when the period is at least 3.0 robust standard deviations above the company's own median, with 6+ earlier periods, 540+ days of history and a value of at least $10.0M.

    Check it at the source: SEC EDGAR quarterly reports.

  38. 21 Oct 2023Lobbying record

    ALKERMES, INC.: lobbying engagement terminated (FEDERAL STREET STRATEGIES, LLC) (dated 30 Sep 2023)

  39. 20 Oct 2023Lobbying record

    ALKERMES, INC.: lobbying engagement terminated (THE MCMANUS GROUP) (dated 31 Aug 2023)

  40. 1 Aug 2023Financials change

    reported revenue of $617.4M for the quarter ended 30 Jun 2023, 2.2× the same quarter last year.

    Same quarter last year: $276.2M; its normal quarter is $290.9M.

    See the evidence
    This period
    $617.4M (the quarter ended 30 Jun 2023)
    Normal quarter (median of 8 earlier)
    $290.9M
    Typical spread (median absolute deviation)
    $13.3M
    How far from its usual level
    +11.2
    Same quarter last year
    $276.2M
    History used
    4,656 days
    2021-06-30: $303.7M2021-09-30: $294.1M2021-12-31: $324.5M2022-03-31: $278.5M2022-06-30: $276.2M2022-09-30: $252.4M2022-12-31: $304.7M2023-03-31: $287.6M2023-06-30: $617.4M
    the quarter ended 30 Jun 20238 earlier quartersnormal: $290.9M

    Fires when the period is at least 3.0 robust standard deviations above the company's own median, with 6+ earlier periods, 540+ days of history and a value of at least $10.0M.

    Check it at the source: SEC EDGAR quarterly reports.

Showing the newest 40 of 135 entries; narrow the window or the kind of data to see older ones.

Not listed: 360 routine records (quarterly and annual reports, results releases, other 8-K items, material agreements and individual insider sales), counted over all history.

Identifiers and sources

How records are matched to this company, and what each source holds for it

Cik
0001520262
Ticker
ALKS
Domain
alkermes.com
Employer name
ALKERMES, INC. (1 unverified)
Hq location
L2|DUBLIN 4|00000 (1 unverified)
Lobbying client
alkermes, avadel pharmaceuticals
Name
Alkermes Finance Ireland (No 3) Limited, Alkermes Finance LLC, Alkermes Inc. plc, Alkermes Ireland Holdings Limited and 17 more
Uei
L6XLUBSCA6T5, N5NJLD2JVLB5, XKVDMLKZJUE5, ZFZ6DN7GVL53
  • DOL H-1B labor condition applications and PERM certifications621 data points1 Oct 2019 to 28 Sep 2026
  • Federal lobbying disclosures (LDA)57 records, 229 data points30 Dec 1899 to 30 Sep 2026
  • SEC Form 13F institutional holdings1 record, 481 data points30 Jun 2013 to 30 Sep 2026
  • SEC EDGAR filings (8-K items, S-1, Form D, 10-K/10-Q)176 records25 Feb 2016 to 12 Nov 2026
  • SEC XBRL company facts (revenue, capex, R&D, backlog...)1162 data points31 Mar 2009 to 30 Oct 2026
  • SEC Form 4 insider transactions228 records, 692 data points4 Jan 2016 to 3 Nov 2026
  • FINRA short interest (twice monthly)636 data points29 Dec 2017 to 30 Oct 2026
  • FINRA daily short sale volume (off-exchange)4174 data points1 Aug 2018 to 20 Nov 2026
  • USASpending.gov federal awards1 record, 9 data points30 Sep 2010 to 2 Aug 2012